Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy
05 Diciembre 2023 - 10:45AM
Business Wire
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech
company that designs and develops virus-based immunotherapies for
the treatment of cancer, is pleased to announce the appointment of
Arnaud Dubarry as Chief Financial Officer (CFO), effective January
1, 2024. Arnaud Dubarry will be based in Strasbourg and will be
responsible for all aspects of the Company’s financial strategy,
management and operations to accelerate the development of its
innovative immunotherapy pipeline. Arnaud Dubarry succeeds
Jean-Philippe Del who will stay until the end of the current year
to ensure a smooth transition.
Arnaud Dubarry has over 20 years of experience in
leading financial positions in the pharmaceutical and biotech
industry. Prior to joining Transgene, he served as Executive
Finance Director at Gilead, where he led a major strategic
transformation of the global finance function. With decades of
professional experience at Gilead and Johnson & Johnson, both
in Europe and the USA, Arnaud Dubarry gained considerable financial
expertise in a variety of entities, covering commercial structures,
production sites, R&D centers as well as headquarters. Arnaud
is a graduate of the Paris Institute of Political Studies (Sciences
Po). He also holds a Master’s degree in Management Sciences from
Université Paris-IX Dauphine, as well as a Professional Certificate
in Finance and Accounting from The Wharton School of the University
of Pennsylvania.
Alongside this new appointment, Transgene has promoted Lucie
Larguier to Vice President Corporate Communications and Investor
Relations with immediate effect. Lucie joins the executive
management team, where she will bring a cross-functional view of
the Company’s operations and how these can be articulated to key
stakeholders including financial market participants. Since 2016,
Lucie has served as Director Corporate Communications and Investor
Relations, reporting to the CEO. Her strategic contribution helped
to ensure the smooth execution of four successful securities
transactions, as well as multiple scientific, clinical and
corporate announcements, including the recent promising initial
data on the individualized cancer vaccine TG4050. Prior to joining
Transgene, Lucie spent more than 10 years in the consultancy
environment, advising companies on their corporate and financial
messages, and contributed to the success of numerous securities
transactions. She is a graduate of the Paris Institute of Political
Studies (Sciences Po), with a Master’s degree in Communication with
a minor in finance.
Alessandro Riva, MD, Chairman and CEO of Transgene,
comments: “Arnaud is a results-driven CFO in the pharmaceutical
and biotech industry and his extensive expertise and leadership
capabilities will enable us to accelerate Transgene’s growth and
support the Company’s ambition in the fast-evolving landscape of
immunotherapy. I am looking forward to working with him. I also
extend a warm welcome to Lucie from the executive committee. I am
sure she will contribute further to the Company’s success thanks to
her significant equity capital markets expertise, her ability to
articulate Transgene’s strategy and her deep knowledge of the
investment community.
Dr. Riva added: “I would like to take this opportunity to
also thank Jean-Philippe Del for his long-standing commitment to
Transgene and his ability to support Transgene’s operations through
multiple successful transactions on the financial markets and with
business partners.”
Arnaud Dubarry, Chief Financial Officer, said: “I am
excited to join the Transgene team. The company has developed a
particularly innovative technology in the immune-oncology field
with the potential to generate game-changing value for all
stakeholders. I am looking forward to contributing to shaping the
company's future and collaborating with the entire team to build on
its success.”
***
About Transgene Transgene (Euronext: TNG) is a
biotechnology company focused on designing and developing targeted
immunotherapies for the treatment of cancer. Transgene’s programs
utilize viral vector technology with the goal of indirectly or
directly killing cancer cells. The Company’s clinical-stage
programs consist of a portfolio of therapeutic vaccines and
oncolytic viruses: TG4050, the first individualized therapeutic
vaccine based on the myvac® platform, TG4001 for the treatment of
HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic
viruses based on the Invir.IO® viral backbone. With Transgene’s
myvac® platform, therapeutic vaccination enters the field of
precision medicine with a novel immunotherapy that is fully
tailored to each individual. The myvac® approach allows the
generation of a virus-based immunotherapy that encodes
patient-specific mutations identified and selected by Artificial
Intelligence capabilities provided by its partner NEC. With its
proprietary platform Invir.IO®, Transgene is building on its viral
vector engineering expertise to design a new generation of
multifunctional oncolytic viruses. Additional information about
Transgene is available at: www.transgene.fr Follow us on social
media: X (ex-Twitter): @TransgeneSA – LinkedIn: @Transgene
Disclaimer This press release contains forward-looking
statements, which are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
anticipated. The occurrence of any of these risks could have a
significant negative outcome for the Company’s activities,
perspectives, financial situation, results, regulatory authorities’
agreement with development phases, and development. The Company’s
ability to commercialize its products depends on but is not limited
to the following factors: positive pre-clinical data may not be
predictive of human clinical results, the success of clinical
studies, the ability to obtain financing and/or partnerships for
product manufacturing, development and commercialization, and
marketing approval by government regulatory authorities. For a
discussion of risks and uncertainties which could cause the
Company’s actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque”)
section of the Universal Registration Document, available on the
AMF website (http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made, and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231205509214/en/
Transgene: Lucie Larguier Director Corporate
Communications & IR +33 (0)3 88 27 91 04
investorrelations@transgene.fr
Media: MEDiSTRAVA Consulting Frazer Hall /Sylvie
Berrebi +44 (0)203 928 6900 transgene@medistrava.com
Transgene (EU:TNG)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Transgene (EU:TNG)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024